Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > Here’s the problem

<< Previous

Bullboard Posts

Next >>

Comment by Rosmorducon Mar 09, 2020 4:59pm

82 Views

Post# 30785355

RE:Here’s the problem

The data shows that not only CAPRE works but it works exceptionally well. Look at the CAPRE data only witout the placebo or take the placebo from any other drug and you will see the hypocrisy.

The placebo from those 5 suspect sites are being investigated by the company and key outside experts. Once the study is reviewed with the FDA, the FDA will get this resolved as no placebo should have those peaks and valleys and that range.

Trilogy 2 will be a Babe Ruth Grand Slam, the shot that will be heard around the world. Clonk!!!

<< Previous

Bullboard Posts

Next >>

UniDoc brings AI-powered H3 Health Cube to Italy